BIOMAT Database Logo BIOMAT Database Logo

A 3D QSAR CoMFA study of non-peptide angiotensin II receptor antagonists. 1996

L Belvisi, and G Bravi, and G Catalano, and M Mabilia, and A Salimbeni, and C Scolastico
Organic and Industrial Chemistry Department, C.N.R. (National Research Council), University of Milan, Italy.

A series of non-peptide angiotensin II receptor antagonists was investigated with the aim of developing a 3D QSAR model using comparative molecular field analysis descriptors and approaches. The main goals of the study were dictated by an interest in methodologies and an understanding of the binding requirements to the AT1 receptor. Consistency with the previously derived activity models was always checked to contemporarily test the validity of the various hypotheses. The specific conformations chosen for the study, the procedures invoked to superimpose all structures, the conditions employed to generate steric and electrostatic field values and the various PCA/PLS runs are discussed in detail. The effect of experimental design techniques to select objects (molecules) and variables (descriptors) with respect to the predictive power of the QSAR models derived was especially analysed.

UI MeSH Term Description Entries
D007093 Imidazoles Compounds containing 1,3-diazole, a five membered aromatic ring containing two nitrogen atoms separated by one of the carbons. Chemically reduced ones include IMIDAZOLINES and IMIDAZOLIDINES. Distinguish from 1,2-diazole (PYRAZOLES).
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D008968 Molecular Conformation The characteristic three-dimensional shape of a molecule. Molecular Configuration,3D Molecular Structure,Configuration, Molecular,Molecular Structure, Three Dimensional,Three Dimensional Molecular Structure,3D Molecular Structures,Configurations, Molecular,Conformation, Molecular,Conformations, Molecular,Molecular Configurations,Molecular Conformations,Molecular Structure, 3D,Molecular Structures, 3D,Structure, 3D Molecular,Structures, 3D Molecular
D005069 Evaluation Studies as Topic Works about studies that determine the effectiveness or value of processes, personnel, and equipment, or the material on conducting such studies. Critique,Evaluation Indexes,Evaluation Methodology,Evaluation Report,Evaluation Research,Methodology, Evaluation,Pre-Post Tests,Qualitative Evaluation,Quantitative Evaluation,Theoretical Effectiveness,Use-Effectiveness,Critiques,Effectiveness, Theoretical,Evaluation Methodologies,Evaluation Reports,Evaluation, Qualitative,Evaluation, Quantitative,Evaluations, Qualitative,Evaluations, Quantitative,Indexes, Evaluation,Methodologies, Evaluation,Pre Post Tests,Pre-Post Test,Qualitative Evaluations,Quantitative Evaluations,Report, Evaluation,Reports, Evaluation,Research, Evaluation,Test, Pre-Post,Tests, Pre-Post,Use Effectiveness
D001665 Binding Sites The parts of a macromolecule that directly participate in its specific combination with another molecule. Combining Site,Binding Site,Combining Sites,Site, Binding,Site, Combining,Sites, Binding,Sites, Combining
D001713 Biphenyl Compounds Whitish aromatic crystalline organic compounds made up of two conjoined BENZENE rings. Compounds, Biphenyl
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D013777 Tetrazoles
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D017076 Computer-Aided Design The use of computers for designing and/or manufacturing of anything, including drugs, surgical procedures, orthotics, and prosthetics. CAD-CAM,Computer-Aided Manufacturing,Computer-Assisted Design,Computer-Assisted Manufacturing,Computer Aided Design,Computer Aided Manufacturing,Computer Assisted Design,Computer Assisted Manufacturing,Computer-Aided Designs,Computer-Assisted Designs,Design, Computer-Aided,Design, Computer-Assisted,Designs, Computer-Aided,Designs, Computer-Assisted,Manufacturing, Computer-Aided,Manufacturing, Computer-Assisted

Related Publications

L Belvisi, and G Bravi, and G Catalano, and M Mabilia, and A Salimbeni, and C Scolastico
Novel non-peptide angiotensin II receptor antagonists.
January 1992, Proceedings of the Western Pharmacology Society,
L Belvisi, and G Bravi, and G Catalano, and M Mabilia, and A Salimbeni, and C Scolastico
A 3D-QSAR of angiotensin II (AT1) receptor antagonists based on receptor surface analysis.
January 2004, Journal of chemical information and computer sciences,
L Belvisi, and G Bravi, and G Catalano, and M Mabilia, and A Salimbeni, and C Scolastico
Distinctions between non-peptide angiotensin II AT1-receptor antagonists.
March 2001, Journal of the renin-angiotensin-aldosterone system : JRAAS,
L Belvisi, and G Bravi, and G Catalano, and M Mabilia, and A Salimbeni, and C Scolastico
Non-peptide angiotensin II receptor antagonists. II. Pharmacology of S-8308.
November 1988, European journal of pharmacology,
L Belvisi, and G Bravi, and G Catalano, and M Mabilia, and A Salimbeni, and C Scolastico
3D-QSAR and docking studies on adenosine A2A receptor antagonists by the CoMFA method.
June 2015, SAR and QSAR in environmental research,
L Belvisi, and G Bravi, and G Catalano, and M Mabilia, and A Salimbeni, and C Scolastico
Comparative QSAR: angiotensin II antagonists.
September 2001, Chemical reviews,
L Belvisi, and G Bravi, and G Catalano, and M Mabilia, and A Salimbeni, and C Scolastico
Non-peptide angiotensin II receptor antagonists: chemical feature based pharmacophore identification.
February 2003, Journal of medicinal chemistry,
L Belvisi, and G Bravi, and G Catalano, and M Mabilia, and A Salimbeni, and C Scolastico
3D-QSAR modeling of non-peptide antagonists for the human luteinizing hormone-releasing hormone receptor.
June 2013, Medicinal chemistry (Shariqah (United Arab Emirates)),
L Belvisi, and G Bravi, and G Catalano, and M Mabilia, and A Salimbeni, and C Scolastico
Receptor-based QSAR studies of non-peptide human oxytocin receptor antagonists.
January 2007, Journal of molecular graphics & modelling,
L Belvisi, and G Bravi, and G Catalano, and M Mabilia, and A Salimbeni, and C Scolastico
3D QSAR (COMFA) of a series of potent and highly selective VLA-4 antagonists.
March 2002, Journal of computer-aided molecular design,
Copied contents to your clipboard!